Human dominant‐negative class <scp>II</scp> transactivator transgenic pigs – effect on the human anti‐pig <scp>T</scp>‐cell immune response and immune status
Hidetaka Hara(Hainan Medical University), Thomas E. Starzl(University of Pittsburgh Medical Center), Kumiko Isse(University of Pittsburgh), Tanner Crossley(University of Pittsburgh), Yifan Dai(Nanjing Medical University), Cassandra Long(University of Pittsburgh), Liming Fan(North University of China), William Witt(University of Pittsburgh), Carol J. Phelps(Kraft Heinz (United States)), David K. C. Cooper(Massachusetts General Hospital), David Ayares(Kraft Heinz (United States))
Cited by 113
Related Papers
REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY
|The Lancet|1984|1.3k
Production of α1,3-Galactosyltransferase-Deficient Pigs
|Science|2003|1.1k
Evolution of Liver Transplantation
|Hepatology|1982|887
Clinical Pharmacokinetics of Tacrolimus
|Clinical Pharmacokinetics|1995|802
Orthotopic Homotransplantation of the Human Liver
|Annals of Surgery|1968|726